StarTric brought home a clear message from LSI Europe: the clinical evidence that builds enterprise value is the evidence that matters to patients.
StarTric’s CEO, Daniele Zanotti joined an LSI panel in Barcelona discussing clinical decisions that make or break enterprise value, with Carolina Aguilar from INBRAIN Neuroelectronics, Boris Pasche from TheraBionic Inc. and Louise Warme from We Venture Capital and moderated by Sofia Spjuth from Veranex.
Evidence that matters
Daniele’s view is very clear: what counts in the end and can most effectively generate value is the evidence relevant to survival and quality of life. Therefore, the decision with the greatest impact is defining the clinical indication and the detailed intended use of a device.
These are decisions that come very early in the process and are often underestimated. They are drivers of development and validation, show that the technology is meaningful, help keep strong consistency throughout a project and give a solid base to clinical evidence.
The StarTric experience
At StarTric, this meant choosing to focus TriClover™ on access to therapy rather than on maximising therapeutic performance alone, with a technology adaptable to more patients and easier to use.
Daniele explained how that choice has a virtuous domino effect throughout the programme: a larger target population, fewer screening failures in trials, more achievable endpoints, simpler training and greater adoption potential.
He also challenged one of the costliest assumptions in medtech, that a first trial must demonstrate superiority. “Clinical validation should be structured as a scalable ladder, not as a high-jump competition.”
Generating evidence that matters to patients is an exercise that starts at proof-of-concept and carries on throughout. His closing advice to fellow CEOs was simple: think patient.
